Over the course of the projection period, it is anticipated that rising developments and product releases would fuel market expansion. For instance, scientists at IIT Bombay's Tata Institute for Technology and Design are currently attempting to create a locally produced CAR T-cell therapy that is inexpensive for cancer patients in India. A cutting-edge method of treating cancer that boosts the immune system is called immuno-oncology. The most well-known immune-oncology treatment, immune checkpoint inhibitors, has a remarkable overall success rate across a variety of cancers and has received numerous approvals. Even though immuno-oncology drugs are drastically altering the quality of life for people with cancer, managing toxicities and ensuring that healthcare systems are in place still present numerous obstacles. Moreover, a wide range of substances, including proteins, adjuvants, peptides, antibodies, bi-specific compounds, and cellular therapies, are included in the creation of immune-oncology medications.
According to Coherent Market Insights, The market for Immuno-oncology Medications in India is anticipated to reach US$ 265 Mn in 2021 and grow at a CAGR of 13.1% during the following five years (2021 -2028).
Major Players in the India Immune Oncology Drugs Industry:
Merck & Co., Inc.,
The business was founded in 1668, and Rahway, New Jersey serves as its corporate headquarters. Pharmaceuticals, vaccines, biologic therapies, and goods for animal health are all produced by Merck. The company announced in September 2022 that it will acquire the cattle management company Vence for an undisclosed sum and merge it with Merck Animal Health. Merck Animal Health acquired PrognostiX Poultry in February 2021.
Bristol-Myers Squibb
The firm was founded in 1887 and is located in New York, United States. The therapeutic areas in which Bristol Myers Squibb produces prescription drugs and biologics include cancer, HIV/AIDS, cardiovascular illness, insulin, hepatitis, rheumatoid arthritis, and mental conditions. BMS said in June 2022 that it would pay $4.1 billion in cash to purchase Turning Point Therapeutics Inc.
F. Hoffmann-La Roche AG.
The company was established in 1896 and is based in Basel, Switzerland. F. Hoffmann-La Roche AG offers in-vitro diagnostics, as well as cancer and transplant medications. Roche announced in March 2021 that it will pay $1.8 billion to purchase GenMark Diagnostics. The company announced in September 2021 that it will purchase the German biotech company TIB Molbiol in order to expand its molecular diagnostics business.